Cancer Immunotherapy

Current Location

101 Cancer Immunotherapy Trials Near You

Power is an online platform that helps thousands of Cancer Immunotherapy patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

RP3 + Atezolizumab + Bevacizumab for Liver Cancer

Cincinnati, Ohio
The purpose of this study is to evaluate whether treatment with RP2 can provide efficacy as 2L treatment combined with atezolizumab plus bevacizumab in patients with locally advanced unresectable, recurrent, and/or metastatic HCC.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

30 Participants Needed

Vigil Vaccine for Ovarian Cancer

Cincinnati, Ohio
The goal of this clinical trial is to compare participants with ovarian, fallopian tube or primary peritoneal cancer when treated with investigational product (Vigil) compared to placebo. The main question it aims to answer is "Will participants who receive treatment with Vigil have a longer time to disease recurrence versus the participants that were not given Vigil?"

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Sex:Female

92 Participants Needed

LSTA1 + Standard Care for Advanced Cancers

Cincinnati, Ohio
This trial is testing a new drug called LSTA1 combined with standard treatment in patients with advanced cholangiocarcinoma. It aims to find out if this combination is safer and more effective than the standard treatment alone.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

67 Participants Needed

NC410 + Pembrolizumab for Advanced Cancer

Cincinnati, Ohio
This is an open-label, non-randomized, Phase 1b/2 study to determine the safety and tolerability of NC410 when combined with a standard dose of pembrolizumab. This study will also assess the clinical benefit of combination therapy in participants with advanced unresectable and/or metastatic ICI refractory solid tumors OR ICI naïve MSS/MSI-low solid tumors
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

97 Participants Needed

Immunotherapy + Radiation for Head and Neck Cancer

Cincinnati, Ohio
The purpose of this study is to compare any good or bad effects of using pembrolizumab (an experimental drug) and radiation therapy (RT), compared to using cisplatin chemotherapy and radiation therapy (RT) in the treatment of patients with head and neck squamous cell carcinoma (HNSCC).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

114 Participants Needed

RP2/RP3 + Atezolizumab + Bevacizumab for Colorectal Cancer

Cincinnati, Ohio
This is an open-label, Phase 2 clinical trial evaluating therapy with an oncolytic immunotherapy (RP2 or RP3) in combination with atezolizumab and bevacizumab in patients with advanced Microsatellite Stable and Mismatch Repair Proficient Colorectal Carcinoma.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

4 Participants Needed

DF9001 + Nivolumab for Solid Tumors

Cincinnati, Ohio
This trial is testing a new molecule that helps the immune system attack cancer cells. It focuses on patients with solid tumors that have a protein called EGFR. The study will determine the best dose and test its effectiveness alone and with another drug called pembrolizumab. AM0010 has been previously tested in combination with pembrolizumab for advanced cancers.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

242 Participants Needed

SRF114 for Solid Tumors

Cincinnati, Ohio
This is a Phase 1, open-label, first-in-human, dose-escalation and expansion study of CHS-114, a monoclonal antibody that targets CCR8, as a monotherapy in patients with solid tumors.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

87 Participants Needed

Virus Therapy and Chemotherapy for Lung Cancer

Canton, Ohio
This Phase 2, open-label, randomized study in non-small-cell lung cancer (NSCLC) is designed to evaluate the efficacy and safety of an intravenously delivered oncolytic vaccinia virus, Olvi-Vec, followed by platinum-doublet chemotherapy + Physician's Choice of Immune Checkpoint Inhibitor (ICI) vs. docetaxel for patients with advanced or metastatic NSCLC who have shown first disease progression (i.e., progressive disease not yet confirmed by further scan after initial scan showing progression) while on front-line treatment or maintenance ICI therapy after front-line treatment with platinum-doublet chemotherapy + ICI as standard of care.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

142 Participants Needed

Futibatinib + PD-1 Antibody for Esophageal Cancer

Canton, Ohio
This is a nonrandomized, uncontrolled, open-label, multicenter Phase 2 study to evaluate the efficacy, safety, and tolerability of futibatinib in combination with PD-1 antibody-based SoC therapy in adult patients with solid tumors.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

53 Participants Needed

TTFields + Pembrolizumab for Lung Cancer

Edgewood, Kentucky
This is a multicenter, randomized, open-label study of Tumor Treating Fields (TTFields) at 150 kHz to the thorax using the NovoTTF-200T System with IV pembrolizumab in subjects previously untreated for advanced or metastatic, PD-L1 positive non-small cell lung cancer (NSCLC). The primary objective is to evaluate the progression-free survival (PFS) by RECIST 1.1 in subjects with TPS ≥1 percent, 1L metastatic/current advanced NSCLC treated with TTFields concomitant with pembrolizumab compared to those treated with pembrolizumab alone. The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields) to the region of the malignant tumor, by means of surface, insulated electrode arrays.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:22+

100 Participants Needed

NBTXR3 + Radiotherapy for Cancer

Canton, Ohio
The 1100 study is an open-label, Phase I, dose escalation and expansion prospective clinical study to assess the safety of intratumoral injection of NBTXR3 activated by radiotherapy in combination with anti-PD-1 therapy.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

145 Participants Needed

Pembrolizumab + ALE.C04 for Head and Neck Cancer

Canton, Ohio
The purpose of this study is to evaluate the safety profile of ALE.C04 monotherapy and in combination with pembrolizumab, to characterize pharmacokinetics profile of ALE.C04, recommended Phase II dose (RP2D) for ALE.C04 in combination with pembrolizumab and to assess anti-tumor activity of ALE.C04 in combination with pembrolizumab in patients with Head and Neck Cancer.
No Placebo Group

Trial Details

Trial Status:Terminated

21 Participants Needed

ADU-1805 +/- Pembrolizumab for Cancer

Canton, Ohio
This first-in-human, open-label, multicenter, multi-arm dose-escalation study is designed to evaluate the safety, PK, and PD of ADU-1805, an anti- SIRPα monoclonal antibody, as monotherapy and in combination with pembrolizumab (anti-PD-1 antibody).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

90 Participants Needed

MDNA11 + Pembrolizumab for Cancer

Canton, Ohio
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

115 Participants Needed

ProstAtak Immunotherapy for Prostate Cancer

Middleburg Heights, Ohio
This trial is testing CAN-2409, a treatment that kills prostate cancer cells and boosts the immune system to fight the cancer. It targets patients with localized prostate cancer. The treatment aims to improve their health outcomes by helping their immune system attack the cancer.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Sex:Male

187 Participants Needed

VMD-928 for Advanced Cancer

Maumee, Ohio
This trial tests VMD-928, an oral drug, in adults with advanced cancers that don't respond to other treatments. It aims to find a safe and effective dose and understand how the drug affects cancer cells.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

82 Participants Needed

GI-102 for Advanced Cancer

Cleveland, Ohio
This trial is testing GI-102, a new protein treatment, in patients with advanced or spreading tumors. The treatment aims to help the immune system fight cancer by boosting certain immune cells while avoiding those that suppress the response.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

358 Participants Needed

DPX-Survivac + Pembrolizumab for Lymphoma

Toledo, Ohio
This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refractory DLBCL.
No Placebo Group

Trial Details

Trial Status:Recruiting

102 Participants Needed

Immunotherapy Combinations for Cancer

Cleveland, Ohio
The purpose of this study is to demonstrate the safety and preliminary activity with triple combinations of relatlimab in combination with nivolumab and BMS-986205, or in combination with nivolumab and ipilimumab in immunotherapy-naive and pretreated populations across select advanced tumor types.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting

255 Participants Needed

Why Other Patients Applied

"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

ID
Pancreatic Cancer PatientAge: 40

"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

AG
Paralysis PatientAge: 50

"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

ZS
Depression PatientAge: 51

"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

WR
Obesity PatientAge: 58

"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

IZ
Healthy Volunteer PatientAge: 38

Botensilimab + Balstilimab for Colorectal Cancer

Cleveland, Ohio
This trial tests botensilimab alone or with balstilimab in adults with advanced colorectal cancer who didn't respond to previous chemotherapy. The new drugs aim to enhance the immune system's ability to fight cancer.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

234 Participants Needed

Personalized Adaptive Novel Agents for Breast Cancer

Cleveland, Ohio
This trial is testing new medicines along with regular cancer treatment to find the best combinations for breast cancer patients. It focuses on identifying which treatments work best based on specific cancer characteristics. Early signs of success are monitored using MRI scans and tests on blood and tissue samples.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

5000 Participants Needed

Novel Interventions for Colorectal Cancer

Cleveland, Ohio
The main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC).
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

120 Participants Needed

Customized TCR-T Cell Therapy for Cancer

Cleveland, Ohio
This trial tests a new cancer treatment where a patient's immune cells are modified to better fight their cancer. It focuses on patients with advanced solid tumors who have specific genetic markers. The modified cells are designed to recognize and attack cancer cells more effectively.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

840 Participants Needed

AdAPT-001 for Cancer

Cleveland, Ohio
AdAPT-001 is an oncolytic virus that is injected directly into the tumor or via intraarterial administration. The purpose of this study is to find out if AdAPT-001 is safe and tolerable. The next step is to find out if AdAPT-001 if efficacious with or without a checkpoint inhibitor.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

140 Participants Needed

Combination Immunotherapy for Cancer

Cleveland, Ohio
This trial tests a combination of treatments that aim to boost the immune system in patients whose cancer has progressed after previous treatments. Some patients may receive an additional therapy if their disease continues to progress.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

40 Participants Needed

SRF388 + Pembrolizumab for Cancer

Cleveland, Ohio
This trial tests CHS-388, a protein that blocks IL-27, in patients with severe cancers like kidney, liver, and lung cancer. The goal is to see if it helps the immune system fight cancer better.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

260 Participants Needed

DF6002 + Nivolumab for Advanced Cancer

Cleveland, Ohio
This trial is testing a new drug, DF6002, alone and with an existing drug, Nivolumab, in patients with advanced solid tumors. These patients have cancers that are hard to treat with standard methods. DF6002 might help shrink or slow down tumors, while Nivolumab boosts the immune system to fight cancer.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

438 Participants Needed

TSR-022 for Cancer

Toledo, Ohio
This trial is testing TSR-022, a new medicine that helps the immune system fight cancer by blocking a protein called TIM-3. TIM-3 has gained prominence as a potential candidate for cancer immunotherapy, where it has been shown that blocking TIM-3 with other treatments enhances the body's ability to fight tumors and suppress their growth. It targets patients with tumors, especially those who may not respond to standard treatments. The goal is to see if this medicine can help the immune system better attack cancer cells.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

447 Participants Needed

TSR-022 for Advanced Cancer

Toledo, Ohio
This trial is testing TSR-022, a new medicine that helps the immune system fight cancer by blocking a protein called TIM-3. TIM-3 has gained prominence as a potential candidate for cancer immunotherapy, where it has been shown that blocking TIM-3 with other treatments enhances the body's ability to fight tumors and suppress their growth. It targets patients with tumors, especially those who may not respond to standard treatments. The goal is to see if this medicine can help the immune system better attack cancer cells.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

475 Participants Needed

1234

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do Cancer Immunotherapy clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Cancer Immunotherapy clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Cancer Immunotherapy trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Cancer Immunotherapy is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Cancer Immunotherapy medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Cancer Immunotherapy clinical trials?

Most recently, we added Fasting-Mimicking Diet and Immunotherapy for Non-Small Cell Lung Cancer, G207 + Radiation for Pediatric Brain Tumor and HER2 Vaccine for Breast Cancer to the Power online platform.

Popular Searches

By Condition

Depression Clinical Trials

Anxiety Clinical Trials

Schizophrenia Clinical Trials

ADHD Clinical Trials

Bipolar Disorder Clinical Trials

Multiple Sclerosis Clinical Trials

Autism Clinical Trials

Treatment Resistant Depression Clinical Trials

Borderline Personality Disorder Clinical Trials

Social Anxiety Disorder Clinical Trials

Parkinson's Disease Clinical Trials

Alzheimer's Disease Clinical Trials

By Location

Clinical Trials in California

Clinical Trials in Florida

Clinical Trials in Texas

Clinical Trials in New York

Clinical Trials in Ohio

Clinical Trials in Illinois

Clinical Trials in Pennsylvania

Clinical Trials in Michigan

Clinical Trials in North Carolina

Clinical Trials in Massachusetts

Clinical Trials in Missouri

Clinical Trials in Minnesota

Other People Viewed

By Subject

Top Clinical Trials near Hartsdale, NY

Top Clinical Trials near Lansing, MI

Top Hereditary Angioedema Clinical Trials

31 Parkinson's Disease Trials near Denver, CO

Top Skin Cancer Clinical Trials

Top Clinical Trials near Fort Dodge, IA

12 Leiomyosarcoma Trials near Ventura, CA

Top Clinical Trials near Orlando, FL

63 Attention-Deficit/Hyperactivity Disorder (ADHD) Trials near Miami, FL

Top Clinical Trials near Columbus, OH

Top Clinical Trials near Clarksburg, WV

Top Clinical Trials near Nashville, TN

By Trial

Fitusiran for Pediatric Hemophilia

Daratumumab Combination Therapy for Amyloidosis

BCI-Controlled Devices for Motor Disorders

CAR T-cell Therapy for Neuroblastoma

Fetal Cystoscopy for Severe Lower Urinary Tract Obstruction

Oncolytic Virus + Chemotherapy for Breast Cancer

Free Time for Wellness Program for Sedentary Lifestyle

Methadone vs Hydromorphone for Pain Relief in Gynecologic Cancer

Seltorexant for Depression

FAST Spinal Cord Stimulation for Chronic Pain

Chemotherapy + Stem Cell Transplant + Romidepsin for T-Cell Lymphoma

Rivet Shunt for Pulmonary Hypertension with Heart Failure

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial